Trial Profile
A study to investigate vepoloxamer (Carmeseal-MD) for Duchenne muscular dystrophy
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 24 Sep 2016
Price :
$35
*
At a glance
- Drugs Poloxamer 188 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- 07 Sep 2016 According to a Phrixus Pharmaceuticals media release, the US FDA allowed IND application for poloxamer-188 in DMD.
- 19 Jun 2015 New trial record